Financials data is unavailable for this security.
View more
Year on year Nektar Therapeutics had relatively flat revenues (92.06m to 90.12m), though the company grew net income from a loss of 368.20m to a smaller loss of 276.06m. A reduction in the selling, general and administrative costs as a percentage of sales from 100.30% to 85.90% was a component in the net income growth despite flat revenues.
| Gross margin | 59.22% |
|---|---|
| Net profit margin | -190.09% |
| Operating margin | -175.59% |
| Return on assets | -42.28% |
|---|---|
| Return on equity | -128.02% |
| Return on investment | -48.54% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Nektar Therapeutics fell by 52.95m. However, Cash Flow from Investing totalled 139.56m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 192.61m for operations while cash generated from financing totalled 30.00k.
| Cash flow per share | -0.8696 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 0.4329 |
|---|---|
| Tangible book value per share | 0.4329 |
More ▼
Balance sheet in USDView more
| Current ratio | 5.15 |
|---|---|
| Quick ratio | 4.90 |
| Total debt/total equity | 0.00 |
|---|---|
| Total debt/total capital | 0.00 |
More ▼
